Influence of Race/Ethnic Origin on the Pharmacokinetics of SCH 527123 (in Healthy Volunteers).
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Navarixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Schering-Plough
- 19 Dec 2013 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
- 14 May 2009 New trial record